» Articles » PMID: 36350653

Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution

Abstract

Importance: Persistent symptoms after SARS-CoV-2 infection are an emerging public health problem. The duration of these symptoms remains poorly documented.

Objective: To describe the temporal dynamics of persistent symptoms after SARS-CoV-2 infection and the factors associated with their resolution.

Design, Setting, And Participants: This cross-sectional study involved 53 047 participants from 3 French adult population-based cohorts (CONSTANCES [Consultants des Centres d'Examens de Santé], E3N/E4N, and Nutrinet-Santé) who were included in a nationwide survey about SARS-CoV-2 infection. All participants were asked to complete self-administered questionnaires between April 1 and June 30, 2020. Variables included sociodemographic characteristics, comorbid conditions, COVID-19 diagnosis, and acute symptoms. Blood samples were obtained for serologic analysis between May 1 and November 30, 2020, from patients with SARS-CoV-2 infection defined as enzyme-linked immunosorbent assay immunoglobulin G antispike detection confirmed with a neutralization assay. A follow-up internet questionnaire was completed between June 1 and September 30, 2021, with details on persistent symptoms, their duration, and SARS-CoV-2 infection diagnosis by polymerase chain reaction.

Main Outcomes And Measures: Persistent symptoms were defined as symptoms occurring during the acute infection and lasting 2 or more months. Survival models for interval-censored data were used to estimate symptom duration from the acute episode. Multivariable adjusted hazard ratios (HRs) were estimated for age, sex, and comorbid conditions. Factors associated with the resolution of symptoms were assessed.

Results: A total of 3972 participants (2531 women [63.7%; 95% CI, 62.2%-65.2%]; mean [SD] age, 50.9 [12.7] years) had been infected with SARS-CoV-2. Of these 3972 participants, 2647 (66.6% [95% CI, 65.1%-68.1%]) reported at least 1 symptom during the acute phase. Of these 2647 participants, 861 (32.5% [95% CI, 30.8%-34.3%]) reported at least 1 persistent symptom lasting 2 or more months after the acute phase. After 1 year of follow-up, the estimated proportion of individuals with complete symptom resolution was 89.9% (95% CI, 88.7%-90.9%) with acute symptoms. Older age (>60 years; HR, 0.78; 95% CI, 0.68-0.90), female sex (HR, 0.64; 95% CI, 0.58-0.70), history of cancer (HR, 0.61; 95% CI, 0.47-0.79), history of tobacco consumption (HR, 0.80; 95% CI, 0.73-0.88), high body mass index (≥30: HR, 0.75; 95% CI, 0.63-0.89), and high number of symptoms during the acute phase (>4; HR, 0.43; 95% CI, 0.39-0.48) were associated with a slower resolution of symptoms.

Conclusions And Relevance: In this cross-sectional study, persistent symptoms were still present in 10.1% of infected individuals at 1 year after SARS-CoV-2 infection. Given the high level of cumulative incidence of COVID-19, the absolute prevalent number of people with persistent symptoms is a public health concern.

Citing Articles

Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis.

Xu H, Lu T, Liu Y, Yang J, Ren S, Han B Front Oncol. 2025; 14:1506366.

PMID: 39882453 PMC: 11774732. DOI: 10.3389/fonc.2024.1506366.


Factors influencing the course of post-COVID-19-related symptoms: A bidirectional cohort study among employees in health and welfare services in Germany.

Steinke L, Peters C, Nienhaus A, Bethge M, Koch P GMS Hyg Infect Control. 2024; 19:Doc61.

PMID: 39677013 PMC: 11638722. DOI: 10.3205/dgkh000516.


Vitamin D deficiency and duration of COVID-19 symptoms in UK healthcare workers.

Chadda K, Roberts S, Lugg S, Faniyi A, Faustini S, Webster C Front Med (Lausanne). 2024; 11:1494129.

PMID: 39655234 PMC: 11625565. DOI: 10.3389/fmed.2024.1494129.


Factors associated with the development, severity, and resolution of post COVID-19 condition in adults living in Canada, January 2020 to August 2022.

Zakaria D, Demers A, Cheta N, Aziz S, Abdullah P Can J Public Health. 2024; .

PMID: 39485635 DOI: 10.17269/s41997-024-00958-7.


How Long Is Long COVID? Evaluation of Long-Term Health Status in Individuals Discharged from a Specialist Community Long COVID Service.

Bodey R, Grimaldi J, Tait H, Godfrey B, Witton S, Shardha J J Clin Med. 2024; 13(19).

PMID: 39407877 PMC: 11477015. DOI: 10.3390/jcm13195817.


References
1.
Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

2.
Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G . Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Intern Med. 2021; 182(1):19-25. PMC: 8576624. DOI: 10.1001/jamainternmed.2021.6454. View

3.
Hirschenberger M, Hunszinger V, Sparrer K . Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections. Cells. 2021; 10(8). PMC: 8391718. DOI: 10.3390/cells10082134. View

4.
Sudre C, Murray B, Varsavsky T, Graham M, Penfold R, Bowyer R . Attributes and predictors of long COVID. Nat Med. 2021; 27(4):626-631. PMC: 7611399. DOI: 10.1038/s41591-021-01292-y. View

5.
Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G . Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022; 13(1):1957. PMC: 9005552. DOI: 10.1038/s41467-022-29521-z. View